Key Points
- Insider sale: Moderna President Stephen Hoge sold 160,009 shares on Feb. 23 at an average of $48.84 for about $7.815 million, reducing his holdings by 9.89% to 1,457,427 shares (≈$71.18M).
- Company results and sentiment: Moderna beat estimates with Q EPS of -$2.11 and revenue of $678M (down 33% YoY) but remains unprofitable with negative margins, and analysts' average rating is "Reduce" with a $31.87 target.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 160,009 shares of the company's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president owned 1,457,427 shares in the company, valued at $71,180,734.68. This represents a 9.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Moderna Trading Up 1.4%
Shares of Moderna stock opened at $52.09 on Thursday. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $55.20. The stock has a 50 day moving average price of $40.25 and a two-hundred day moving average price of $30.97. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. The stock has a market capitalization of $20.57 billion, a PE ratio of -7.16 and a beta of 1.32.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. Moderna's revenue was down 33.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.91) EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.
Institutional Trading of Moderna
A number of large investors have recently added to or reduced their stakes in the stock. Capital World Investors bought a new stake in Moderna in the fourth quarter worth about $378,299,000. Norges Bank purchased a new stake in shares of Moderna during the 2nd quarter worth approximately $94,910,000. Alyeska Investment Group L.P. bought a new stake in shares of Moderna in the 4th quarter worth approximately $95,209,000. Federated Hermes Inc. lifted its stake in Moderna by 364.5% in the second quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company's stock valued at $79,163,000 after purchasing an additional 2,251,497 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Moderna by 19.1% in the second quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company's stock valued at $244,458,000 after purchasing an additional 1,420,690 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently issued reports on MRNA shares. The Goldman Sachs Group upped their target price on shares of Moderna from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 17th. Piper Sandler raised their price target on shares of Moderna from $63.00 to $69.00 and gave the company an "overweight" rating in a research report on Monday. Sanford C. Bernstein reaffirmed a "market perform" rating and issued a $45.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. Berenberg Bank set a $28.00 price objective on shares of Moderna in a research note on Monday, November 17th. Finally, Evercore set a $35.00 target price on shares of Moderna in a research report on Tuesday, February 17th. Two investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Reduce" and an average target price of $31.87.
Check Out Our Latest Stock Report on Moderna
About Moderna
(
Get Free Report)
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
